Bronchiolitis is the main cause of respiratory insufficiency in infants, characterized by acute inflammation, edema, necrosis of epithelial cells and increased mucus production. Mucus is mainly purulent and consequently rich in DNA, as derived from nuclei of degenerating neutrophils and epithelial debris. The treatment is mainly supportive; bronchodilators and systemic steroids are often used but do not reduce the length of hospital stay. The aim of our study is to evaluate the efficacy of recombinant human DNase (rhDNase), in infants affected by moderate-severe bronchiolitis. In a randomized doubleblind placebo-controlled study, twenty-two infants (12 males) under 6 months of age (median age 1.6 months) were enrolled and randomly assigned to receive either nebulized rhDNase or placebo (saline) at a dose of 2.5 ml once a day for three days. All infants were evaluated, based on a clinical assessment Score, on admission and four times daily during the hospitalization. Placebo and study groups were sex-and age-matched and were similar in terms of clinical severity on admission. No differences were observed between the two groups of patients with regard to the length of hospitalization and clinical score during the days observed. Two out of four infants, all in the study group, presenting atelectasis on chest radiographs, showed a rapid improvement on the first day. RhDNase is not an effective routine therapy in treating infants hospitalized for bronchiolitis and it is not useful in preventing severe forms of the disease. On the contrary, it may be an effective, safe and cost-benefit treatment only in infants with bronchiolitis and massive atelectasis.
Bronchiolitis is the most common cause of lower respiratory tract infection in infants and is the major responsible factor of hospitalization in infants under one year of age, with the highest incidence occurring from December to March (1) . It is characterized by acute inflammation, edema and necrosis of epithelial cells lining small airways and increased mucus production. Respiratory Syncyzial Virus (RSV) is the most common cause of lower respiratory tract viral infection, but also other respiratory viruses (2) (3) are able to cause bronchiolitis in young infants.
Most infants affected by bronchiolitis develop mild illness, consisting of runny nose and dry cough with mild retraction, auscultatory wheezing and diffuse crackles, but sometimes tachypnea, tachycardia, cyanosis, and apneic spells associated with feeding problems occur, particularly in children with risk factors, such as neonates born prematurely or with pre-existing cardiac or respiratory diseases (3) . Even if bronchiolitis is generally a self-limiting condition, approximately I% of infants with bronchiolitis need hospitalization, usually during the seasonal epidemic, but the hospitalization rate increases in younger infants and when risk factors are present (4). To date, there has not been a consensus about the optimal treatment (5) which is mainly supportive, with supplemental oxygen, nasal washing, IV fluids and eventual mechanical ventilation. Clinical trials including~2-agonists (6-7), glucocorticoids (8) , epinephrine (9) in bronchiolitis have been very controversial. Routine use of those different therapies is costly and ineffective, but a personalized strategy must be found for each infant in order to reduce hospital stay and health-care expenditures for this disease.
Pathophysiologically, the infectious inflammation of bronchioles from 75 to 300 urn in diameter, leads to thick mucus plugs, in which DNA is present in a large amount (3 to 14 mg/ml), as derived from nuclei of degenerating neutrophils and epithelial debris. DNA is a polyanion molecular compound improving the mucus viscosity, that contributes to the degeneration of the airways, partially or completely occluded (10) .
Recombinant human DNase (rhDNase) is a mucolytic agent known to liquefy mucus in vitro (11) and its efficacy has been well-documented in patients with cystic fibrosis (12) (13) , while it is also effective in patients with asthma (14) , primary ciliary dyskinesia (15) and Kartagener's syndrome (16) . Moreover, rhDNase has been proved to playa role in the treatment of children with atelectasis (17) . This therapy has already been proposed in infants with bronchiolitis, but it was excluded in the first attempt (18) . We assumed this therapy to be effective also in infants hospitalized for moderate-severe bronchiolitis, in terms of daily clinical improvement and length of hospital stay.'
MATERIALS AND METHODS

Study design
A randomized, double-blind, placebo-controlled study was performed. Twenty-two infants (12 males) under 6 months of age (median age 1.6 months), who consecutively attended the Paediatric Department of the "Sapienza" University of Rome, over the period December I" 2005 -February 28 th 2006, with a clinical diagnosis of bronchiolitis, participated in the study. All patients -who were hospitalized by the attending emergency doctors -were enrolled within 24 h of hospital admission, and chest radiographs (XR) were obtained. They were examined on admittance and four times daily during the hospitalization.
At the time of admission, after parental consent was given, all patients were randomly assigned to receive either nebulized rhDNase or placebo (saline) at a dose of 2.5 ml once a day for three days, while hospitalized for bronchiolitis. The randomization was conducted using a random table sample with each number corresponding to a pack of three doses of the drug/placebo. Throughout the study, both physicians/nurses and parents were blinded in respect to the study or placebo groups. All patients received the drug with the same nebulizing equipment. The allocation codes were not opened until the trial was completed.
Patients
Patients were enrolled according to the following criteria: I) previously healthy full-term neonates; 2) six months of age or less at the time ofthe observation; and 3) a clinical severity scorẽ 4. Fig. I shows the clinical severity score that ranges from 0 to 10 (9). Written, informed consent was obtained from the parents of each child and an ad-hoc questionnaire was filled in. Oxygen supplementation, intravenous fluids or salbutamol nebulized treatment were administered to each subject as decided by the attending physician according to the hospital guidelines. The study was performed according to the Declaration of Helsinki and to the ethical committee of the Policlinico Umberto I, Rome, Italy. All subjects were informed of the objectives of the study.
Daily clinical assessment scoring
Patients were examined four times daily by one of the authors, all blind to the patient assignment. Oxygen saturation, presence of retractions, respiratory rate, feeding evaluation and auscultatory rale presence were evaluated daily. A mean total score of the four evaluations was assigned daily. Length of hospital stay, days until patients were ready for discharge, days for weight recovery and daily clinical score reduction were evaluated in the two groups.
Virology studies
Viral isolation and quantification were performed from nasopharyngeal swab specimens obtained from patients on admission. A panel of PCR or nested PCR assays were developed for detection of viruses including: RSV, influenza A and B, adenovirus, rhinovirus and parainfluenza.
Statistical analysis
A standard statistical package was used for comparisons between groups (SPSS version 13.0, Chicago, IL). X 2 and Fisher's Exact test were used to compare frequency distributions obtained from the two groups.
RESULTS
A total of 22 infants participated in the study, all of whom were enrolled in a time span of 24 hours from admission to hospital. Eleven infants were randomly assigned to the study group and eleven to the control group. The two groups ofpatients resulted age-and sex-matched and no differences in terms of anthropometric parameters (age, height and weight) recorded and clinical score on admission were found, as shown in Table I . Therapy (bronchodilators) and symptomatic days before the hospitalization (range: 1-4) did not differ in the two groups ofpatients. Overall, rhDNase treatment had no statistically significant effect on the parameters evaluated. No adverse effects were registered and no patients interrupted the study. Table II shows viral detection, clinical score reduction and the percentages of these reductions in the two groups of patients. RSV infection was detected in 91% of the placebo group and in 73% of the study group; rhinovirus infection was found in one case in the placebo group and in two cases ofthe study group. The length of hospitalization and days for weight recovery did not differ between the two groups (Table   I ).
In the study group, four infants presented atelectasis when undergoing a chest X-ray. Two of them, who had massive atelectasis, showed a distinct improvement during the first two days. Two subjects in the study group showed a worsening of the clinical score. They were one month-old males, one with rhinovirus infection and the other with RSV bronchiolitis. 
DISCUSSION
This double-blind placebo-controlled study, suggests the usefulness of rhDNase which is not routinely used in infants hospitalized for bronchiolitis. Furthermore, it seems that it may be useful for patients with severe bronchiolitis and massive atelectasis. Bronchiolitis is a frequent disease that may predispose to long-term problems 0-3). Many efforts have been made to find the optimal therapy (5-10). To date, once plugging of the airways has occurred, no treatment is effective except for respiratory support, oxygen and time.
RhDNase proved to resolve atelectasis in many respiratory diseases (12) (13) (14) (15) (16) (17) . Moreover, some clinical trials investigated its effectiveness also in patients with bronchiolitis, in terms ofchest XR improvement (19) , mucus mobilization (20) or length of hospital stay (18) . In our study, rhDNase did not influence the parameters evaluated. This may be due to the different stage of the disease on admission and to the short hospital stay, infants being usually discharged When clinical conditions are stable, but prior to the completed resolution of the disease. Moreover, the infants enrolled were mainly affected by only mild airway obstruction, without large atelectasis, many of them not being oxygen-dependent.
We are in agreement with the multicenter study of Boogaard et al. (18) , who concluded that inhaled rhDNase does not reduce the length of hospital stay or the duration of supplemental oxygen, which is not recommended as a first attempt in infants affected with bronchiolitis. In our study, a marked clinical improvement was registered in patients (with RSV bronchiolitis) with atelectasis when the chest X-rays were carried out. However, all of them were in the study group, therefore it was impossible to compare them with and without the rhDNase therapy.
A clinical worsening was detected in two patients of the study group. We can speculate that they were enrolled at the first stage ofthe disease. However, the drug seems not to have been effective in preventing severe forms of bronchiolitis.
Otherwise, we can imagine that young infants, especially when sick, may not be strong enough to cough effectively to expectorate liquefied mucus. Better results could be expected if rhDNase were combined with airway clearance therapy. The rhDNase therapy was safe, easy to administer and well-accepted, and no patient dropped out ofthe study nor showed any side-effects. The dosage was chosen according to the experience with cystic fibrosis subjects but, on the basis of the critical improvement registered in some patients, we have no reason to increase the dose or to extend the treatment.
In conclusion rhDNase is not routinely indicated for all cases of bronchiolitis and is probably not effective in preventing severe forms of the disease, but it may be an effective, safe and cost-benefit treatment for infants with severe bronchiolitis and atelectasis.
